{"entity":{"id":"ltz-301","kind":"drug","name":"LTZ-301","aka":[],"tldr":"LTZ-301 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma and other cancers.","summary":"LTZ-301 is a bispecific antibody (myeloid cell engager) from LTZ Therapeutics. A bispecific myeloid engager that redirects monocytes and macrophages to CD79b-positive B cells and depletes them by Fc-receptor-independent antibody-dependent cellular phagocytosis. Its furthest stage is phase 1, for relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. ClinicalTrials.gov registers it in one study linked below. FDA IND cleared February 2025; phase 1 recruiting (NCT07121946). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"LTZ Therapeutics: ltztherapeutics.com","url":"https://www.ltztherapeutics.com/html/news/118.html"},{"label":"LTZ Therapeutics: ltztherapeutics.com","url":"https://www.ltztherapeutics.com/pipeline/index.html"},{"label":"ClinicalTrials.gov: trials of LTZ-301","url":"https://clinicaltrials.gov/search?intr=LTZ-301"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl","mantle-cell-lymphoma","follicular-lymphoma","marginal-zone-lymphoma"],"sections":[],"technologies":[],"targets":["cd79b"],"drugs":[],"companies":["ltz-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07121946"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"LTZ-301","modality":"Bispecific antibody (myeloid cell engager)","mechanism":"A bispecific myeloid engager that redirects monocytes and macrophages to CD79b-positive B cells and depletes them by Fc-receptor-independent antibody-dependent cellular phagocytosis.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ltz-301/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/"}],"company":[{"id":"ltz-therapeutics","kind":"company","name":"LTZ Therapeutics","route":"/companies/ltz-therapeutics/"}],"trial":[{"id":"nct07121946","kind":"trial","name":"This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","route":"/trials/nct07121946/"}]}}